Assisted Reproductive Technology Market Size To 2022

Assisted Reproductive Technology Market Worth $29.3bn
By 2022
The global assisted reproductive technology market is expected to reach USD 29.3 billion by
2022, according to a new report by Grand View Research Inc. Growing prevalence of stress and
increase in the pollution levels coupled with the changing lifestyle habits including smoking and
drinking are expected to drive the assisted reproductive technology market over the forecast
period.
Growing incidence rate of male and female infertility due to low sperm count, poor sperm
movement, blocked sperm ducts, and fallopian tubes blockage coupled with problems in uterus
or cervix, respectively is expected to significantly contribute towards market growth.
Medical tourism is instrumental in facilitating growing demand of assisted human reproductive
technology. Although, these technologies are widely used in the developed economies of the
U.S. and Canada, entailed high costs render these services unavailable to every patient. Nations
are regulated by stringent laws and govern the transactions between surrogates, egg donors, and
those who are willing to avail these services.
View summary of this report @ http://www.grandviewresearch.com/industryanalysis/assisted-reproductive-technology-market
U.S. assisted reproductive technology market, by procedure, 2012-2022, (USD Million)
Request free sample of this Report @ http://www.grandviewresearch.com/industryanalysis/assisted-reproductive-technology-market
Table of Contents
Chapter 1. Methodology and Scope
1.1. Research methodology
1.2. Research scope & assumption
1.3. List of data sources
Chapter 2. Executive Summary
2.1. Assisted Reproductive Technology- Industry Summary and Key Buying Criteria,
2012 - 2022
Chapter 3. Assisted Reproductive Technology Industry Outlook
3.1. Assisted Reproductive Technology market segmentation
3.2. Assisted Reproductive Technology market size and growth prospects, 2012-2022
3.3. Assisted Reproductive Technology market dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key opportunities prioritized
3.5. Industry analysis - Porter's
3.6. Assisted Reproductive Technology company market share, 2014
3.7. Assisted Reproductive Technology market PESTEL analysis, 2014
Chapter 4. Assisted Reproductive Technology Procedure Outlook
4.1. Assisted Reproductive Technology market share by procedure, 2014 & 2022
4.2. Fresh donor market estimates and forecasts, 2012 – 2022 (USD Million)
4.3. Fresh non-donor market estimates and forecasts, 2012 – 2022 (USD Million)
4.4. Frozen donor market estimates and forecasts, 2012 – 2022 (USD Million)
4.5. Frozen non-donor market estimates and forecasts, 2012 – 2022 (USD Million)
4.6. Embryo/Egg banking market estimates and forecasts, 2012 – 2022 (USD Million)
Chapter 5. Assisted Reproductive Technology Regional Outlook
5.1. North America
5.1.1. North America market, by procedure, 2012 – 2022 (USD Million)
5.1.1.1. U.S. market estimates and forecasts
5.1.2. North America market, by procedure, 2012 – 2022 (USD Million)
5.1.2.1. Canada market estimates and forecasts
5.2. Europe
5.2.1. Europe market, by procedure, 2012 – 2022 (USD Million)
5.2.2. North America market, by procedure, 2012 – 2022 (USD Million)
5.2.1.1. UK market estimates and forecasts
5.2.3. North America market, by procedure, 2012 – 2022 (USD Million)
5.2.1.2. Germany market estimates and forecasts
5.2.4. North America market, by procedure, 2012 – 2022 (USD Million)
5.2.1.3. France market estimates and forecasts
5.1.1. North America market, by procedure, 2012 – 2022 (USD Million)
5.2.1.4. Italy market estimates and forecasts
5.1.1. North America market, by procedure, 2012 – 2022 (USD Million)
5.2.1.5. Spain market estimates and forecasts
5.3. Asia Pacific
5.3.1. Asia Pacific market, by procedure, 2012 – 2022 (USD Million)
5.1.1. North America market, by procedure, 2012 – 2022 (USD Million)
5.3.1.1. India market estimates and forecasts
5.1.1. North America market, by procedure, 2012 – 2022 (USD Million)
5.3.1.2. China market estimates and forecasts
5.1.1. North America market, by procedure, 2012 – 2022 (USD Million)
5.3.1.3. Japan market estimates and forecasts
5.4. Latin America
5.4.1. North America market, by procedure, 2012 – 2022 (USD Million)
5.4.1. Latin America market, by procedure, 2012 – 2022 (USD Million)
5.4.1. North America market, by procedure, 2012 – 2022 (USD Million)
5.4.1.1. Mexico market estimates and forecasts
5.1.1. North America market, by procedure, 2012 – 2022 (USD Million)
5.4.1.2. Brazil market estimates and forecasts
5.5. MEA
5.5.1. MEA market, by procedure, 2012 – 2022 (USD Million)
5.1.1. North America market, by procedure, 2012 – 2022 (USD Million)
5.5.1.1. South Africa market estimates and forecasts
Chapter 6. Competitive Landscape
6.1. Cosmos Biomedical
6.1.1. Company Overview
6.1.2. Financial Performance
6.1.3. Product Benchmarking
6.1.4. Strategic Initiatives
6.2. Microm UK Ltd.
6.2.1. Company Overview
6.2.2. Financial Performance
6.2.3. Product Benchmarking
6.2.4. Strategic Initiatives
6.3. Origio
6.3.1. Company Overview
6.3.2. Financial Performance
6.3.3. Product Benchmarking
6.3.4. Strategic Initiatives
6.4. IrvineScientific
6.4.1. Company Overview
6.4.2. Financial Performance
6.4.3. Product Benchmarking
6.4.4. Strategic Initiatives
6.5. Cryolab Ltd.
6.5.1. Company Overview
6.5.2. Financial Performance
6.5.3. Product Benchmarking
6.5.4. Strategic Initiatives
6.6. Parallabs
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. Product Benchmarking
6.6.4. Strategic Initiatives
6.7. European Sperm Bank
6.7.1. Company Overview
6.7.2. Financial Performance
6.7.3. Product Benchmarking
6.7.4. Strategic Initiatives
6.8. Bloom IVF Centre
6.8.1. Company Overview
6.8.2. Financial Performance
6.8.3. Product Benchmarking
6.8.4. Strategic Initiatives
6.9. Ovascience
6.9.1. Company Overview
6.9.2. Financial Performance
6.9.3. Product Benchmarking
6.9.4 Strategic Initiatives
Browse All Reports of this category @
http://www.grandviewresearch.com/industry/biotechnology
Further key findings from the study suggest:




Fresh non-donor was the largest ART market procedure segment in 2014. The fact that
fresh eggs and sperms increase the number of successful pregnancies is expected to drive
segment growth over the forecast period.
Frozen non-donor is identified as the most lucrative segment of assisted reproductive
technology industry. It is expected to grow at a CAGR of over 5.5% over the forecast
period.
North America dominated global demand accounting for USD 8.5 billion in 2014. This is
attributed to rising people awareness and acceptance of people towards gametes
preservation and donation, government funding for in vitro fertilization, and high usage
rate of advanced technologies such as vitrification.
Asia Pacific is expected to witness substantial growth over the forecast period owing to
increasing prevalence of obesity and average maternal age in the emerging markets of
India and China.


The Asia Pacific Initiative
on Reproduction (ASPIRE) task force of clinicians and scientists are involved in the
monitoring and management of fertility and Assisted Reproductive Technology (ART).
Key players of the assisted reproductive technology market include Cosmos Biomedical,
Origio, European Sperm Bank, Cryolab Ltd., Ovascience, Parallabs, Microm UK Ltd.,
Irvine Scientific, and Bloom IVF Centre.
About Grand View Research
Grand View Research, Inc. is a market research and consulting company that provides off-theshelf, customized research reports and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and fact-based research
across a range of industries, from technology to chemicals, materials and energy. With a deepseated understanding of varied business environments, Grand View Research provides strategic
objective insights.
Contact:
Sherry James
Corporate Sales Specialist, U.S.A.
Grand View Research, Inc.
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Website: http://www.grandviewresearch.com/
Blog Site: www.mediafound.org, www.terrapass.org, www.divog.org

The global assisted reproductive technology market is expected to reach USD 29.3 billion by 2022, according to a new report by Grand View Research Inc. Growing prevalence of stress and increase in the pollution levels coupled with the changing lifestyle habits including smoking and drinking are expected to drive the assisted reproductive technology market over the forecast period.